Clinical Observations of Naomaitai Capsules Plus Compound Cerebroprotein Hydrolysate Tablets on Old Patients with Convalescing Cerebral Infarction

Abstract:

Objective: To investigate the clinical effects of Naomaitai capsules plus compound cerebroprotein hydrolysate tablets on old patients with convalescing cerebral infarction. Method: Seventy two subjects were randomly divided into observation group and control group (n=36 each). Both groups were given aspirin enteric-coated tablets to antiplatelet aggregation and were adopted the basic treatment for controlling blood glucose and blood pressure and regulating blood fat. The control group were given compound cerebroprotein hydrolysate tablets, 4 tablets each time, tid; Naomaitai capsules was added to the observation group, 2 capsules each time, tid, all for 8 weeks. Mental state and daily living ability of the two groups were evaluated by mini-mental status examination (MMSE) and activity of daily living scale (ADL). Result: The observation group was higher than the control group in the scores of MMSE (P<0.01) and was lower than the control groups in the scores of ADL (P<0.05); the total effective rate for convalescent stroke in the observation group was superior to the control group (83.33% vs 61.11%) (P<0.05). The total effective rate for treating traditional Chinese medicine symptom in the observation group was superior to the control group (91.67% vs 66.67%) (P<0.05). Conclusion: Naomaitai capsule can significantly improve cognitive function and daily living ability of patients with convalescing cerebral infarction, and has a significant effect on improving the neurologic function of them, thus it can enhance the curative effect for treating disease; it also has obvious improvement on 'Fengtanyuxue' syndrome and can relieve the clinical symptoms so as to improve the curative effect.